Abstract
Aphanizomenon flos-aquae (AFA), commonly known as Klamath algae, is a freshwater cyanobacterium harvested mainly from Upper Klamath Lake (Oregon, USA) and widely marketed as a nutraceutical ingredient. Its biomass is characterized by a rich nutritional profile, including proteins, vitamins, minerals, phycocyanins, phenylethylamine (PEA), mycosporine-like amino acids (MAAs), and other bioactive compounds with antioxidant, anti-inflammatory, and neuromodulatory properties. Preclinical evidence indicates that AFA extracts may exert neuroprotective effects through the modulation of oxidative stress, neuroinflammation, amyloid aggregation, and monoaminergic neurotransmission. Beneficial activities have also been reported in experimental models of inflammatory bowel disease and obesity-related metabolic dysfunction, where AFA reduces inflammation, improves metabolic parameters, and modulates epigenetic pathways. Clinical evidence remains limited but suggests potential benefits as a source of bioavailable vitamin B12 and in improving mood and cognition-related symptoms. Despite its long history of use, safety remains closely linked to product quality, because commercial AFA is predominantly harvested from natural blooms, where contamination by cyanotoxins, heavy metals, and other microorganisms may occur. Overall, AFA represents a promising and sustainable nutraceutical resource, although larger clinical studies and rigorous quality-control strategies are required to fully validate its efficacy and safety.